APO Research
Talk to an analyst

APO RESEARCH · REPORT

Peptide Receptor Radionuclide Therapy (PRRT)

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Peptide Receptor Radionuclide Therapy (PRRT) Market Analysis and Forecast 2026-2032

20 December 2025199 pages

Choose your research edition.

Industry ResearchPeptide Receptor Radionuclide Therapy (PRRT) Industry Research Report 2026110 pages · $2,950 USDIndustry Growth & TrendsGlobal Peptide Receptor Radionuclide Therapy (PRRT) Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Peptide Receptor Radionuclide Therapy (PRRT) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peptide Receptor Radionuclide Therapy (PRRT) Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Peptide Receptor Radionuclide Therapy (PRRT) Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Peptide Receptor Radionuclide Therapy (PRRT) market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Peptide Receptor Radionuclide Therapy (PRRT) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Peptide Receptor Radionuclide Therapy (PRRT) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Peptide Receptor Radionuclide Therapy (PRRT) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Peptide Receptor Radionuclide Therapy (PRRT) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Peptide Receptor Radionuclide Therapy (PRRT) include Aurobindo Pharma, Curium Pharmaceuticals, Lantheus, Mundipharma, Bayer and Novartis, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Peptide Receptor Radionuclide Therapy (PRRT), market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Peptide Receptor Radionuclide Therapy (PRRT), also provides the revenue of main regions and countries. Of the upcoming market potential for Peptide Receptor Radionuclide Therapy (PRRT), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Peptide Receptor Radionuclide Therapy (PRRT) revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Peptide Receptor Radionuclide Therapy (PRRT) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Peptide Receptor Radionuclide Therapy (PRRT) revenue, projected growth trends, production technology, application and end-user industry.

Peptide Receptor Radionuclide Therapy (PRRT) Segment by Company

Aurobindo Pharma

Curium Pharmaceuticals

Lantheus

Mundipharma

Bayer

Novartis

Peptide Receptor Radionuclide Therapy (PRRT) Segment by Type

Midgut Neuroendocrine Tumor

Gastroenteropancreatic Neuroendocrine Tumor

Foregut Neuroendocrine Tumor

Hindgut Neuroendocrine Tumor

Peptide Receptor Radionuclide Therapy (PRRT) Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Peptide Receptor Radionuclide Therapy (PRRT) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Receptor Radionuclide Therapy (PRRT) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peptide Receptor Radionuclide Therapy (PRRT) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Receptor Radionuclide Therapy (PRRT).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Peptide Receptor Radionuclide Therapy (PRRT) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Peptide Receptor Radionuclide Therapy (PRRT) company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Peptide Receptor Radionuclide Therapy (PRRT) revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Peptide Receptor Radionuclide Therapy (PRRT) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Midgut Neuroendocrine Tumor Major Player Table 3. Gastroenteropancreatic Neuroendocrine Tumor Major Player Table 4. Foregut Neuroendocrine Tumor Major Player Table 5. Hindgut Neuroendocrine Tumor Major Player Table 6. Global Peptide Receptor Radionuclide Therapy (PRRT) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospital Pharmacies Major Player Table 8. Online Pharmacies Major Player Table 9. Retail Pharmacies Major Player Table 10. Peptide Receptor Radionuclide Therapy (PRRT) Industry Trends Table 11. Peptide Receptor Radionuclide Therapy (PRRT) Industry Drivers Table 12. Peptide Receptor Radionuclide Therapy (PRRT) Industry Opportunities and Challenges Table 13. Peptide Receptor Radionuclide Therapy (PRRT) Industry Restraints Table 14. Global Peptide Receptor Radionuclide Therapy (PRRT) Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Peptide Receptor Radionuclide Therapy (PRRT) Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Peptide Receptor Radionuclide Therapy (PRRT) Market Share by Region (2021-2026) Table 17. Global Peptide Receptor Radionuclide Therapy (PRRT) Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Peptide Receptor Radionuclide Therapy (PRRT) Market Share by Region (2027-2032) Table 19. Global Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Peptide Receptor Radionuclide Therapy (PRRT) Revenue Market Share by Players (2021-2026) Table 21. Global Peptide Receptor Radionuclide Therapy (PRRT) Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Peptide Receptor Radionuclide Therapy (PRRT) Key Players Headquarters & Area Served Table 23. Global Peptide Receptor Radionuclide Therapy (PRRT) Players, Product Type & Application Table 24. Global Peptide Receptor Radionuclide Therapy (PRRT) Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Peptide Receptor Radionuclide Therapy (PRRT) by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Peptide Receptor Radionuclide Therapy (PRRT) Revenue Market Share by Type (2021-2026) Table 31. Global Peptide Receptor Radionuclide Therapy (PRRT) Revenue Market Share by Type (2027-2032) Table 32. Global Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Peptide Receptor Radionuclide Therapy (PRRT) Revenue Market Share by Application (2021-2026) Table 36. Global Peptide Receptor Radionuclide Therapy (PRRT) Revenue Market Share by Application (2027-2032) Table 37. Aurobindo Pharma Company Information Table 38. Aurobindo Pharma Business Overview Table 39. Aurobindo Pharma Peptide Receptor Radionuclide Therapy (PRRT) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Aurobindo Pharma Peptide Receptor Radionuclide Therapy (PRRT) Product Portfolio Table 41. Aurobindo Pharma Recent Development Table 42. Curium Pharmaceuticals Company Information Table 43. Curium Pharmaceuticals Business Overview Table 44. Curium Pharmaceuticals Peptide Receptor Radionuclide Therapy (PRRT) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Curium Pharmaceuticals Peptide Receptor Radionuclide Therapy (PRRT) Product Portfolio Table 46. Curium Pharmaceuticals Recent Development Table 47. Lantheus Company Information Table 48. Lantheus Business Overview Table 49. Lantheus Peptide Receptor Radionuclide Therapy (PRRT) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Lantheus Peptide Receptor Radionuclide Therapy (PRRT) Product Portfolio Table 51. Lantheus Recent Development Table 52. Mundipharma Company Information Table 53. Mundipharma Business Overview Table 54. Mundipharma Peptide Receptor Radionuclide Therapy (PRRT) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Mundipharma Peptide Receptor Radionuclide Therapy (PRRT) Product Portfolio Table 56. Mundipharma Recent Development Table 57. Bayer Company Information Table 58. Bayer Business Overview Table 59. Bayer Peptide Receptor Radionuclide Therapy (PRRT) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Bayer Peptide Receptor Radionuclide Therapy (PRRT) Product Portfolio Table 61. Bayer Recent Development Table 62. Novartis Company Information Table 63. Novartis Business Overview Table 64. Novartis Peptide Receptor Radionuclide Therapy (PRRT) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Novartis Peptide Receptor Radionuclide Therapy (PRRT) Product Portfolio Table 66. Novartis Recent Development Table 67. North America Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2021-2026) & (US$ Million) Table 68. North America Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2027-2032) & (US$ Million) Table 69. North America Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2021-2026) & (US$ Million) Table 70. North America Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2027-2032) & (US$ Million) Table 71. North America Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 72. North America Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Country (2021-2026) & (US$ Million) Table 73. North America Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Country (US$ Million) & (2027-2032) Table 74. Europe Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2021-2026) & (US$ Million) Table 75. Europe Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2027-2032) & (US$ Million) Table 76. Europe Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2021-2026) & (US$ Million) Table 77. Europe Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2027-2032) & (US$ Million) Table 78. Europe Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 79. Europe Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Country (2021-2026) & (US$ Million) Table 80. Europe Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Country (US$ Million) & (2027-2032) Table 81. China Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2021-2026) & (US$ Million) Table 82. China Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2027-2032) & (US$ Million) Table 83. China Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2021-2026) & (US$ Million) Table 84. China Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2027-2032) & (US$ Million) Table 85. Asia Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2021-2026) & (US$ Million) Table 86. Asia Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2027-2032) & (US$ Million) Table 87. Asia Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2021-2026) & (US$ Million) Table 88. Asia Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2027-2032) & (US$ Million) Table 89. Asia Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 90. Asia Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Region (US$ Million) & (2021-2026) Table 91. Asia Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Region (US$ Million) & (2027-2032) Table 92. SAMEA Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2021-2026) & (US$ Million) Table 93. SAMEA Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2027-2032) & (US$ Million) Table 94. SAMEA Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2021-2026) & (US$ Million) Table 95. SAMEA Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2027-2032) & (US$ Million) Table 96. SAMEA Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 97. SAMEA Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Country (2021-2026) & (US$ Million) Table 98. SAMEA Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Country (US$ Million) & (2027-2032) Table 99. Research Programs/Design for This Report Table 100. Authors List of This Report Table 101. Secondary Sources Table 102. Primary Sources List of Figures Figure 1. Peptide Receptor Radionuclide Therapy (PRRT) Image Figure 2. Global Peptide Receptor Radionuclide Therapy (PRRT) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peptide Receptor Radionuclide Therapy (PRRT) Market Size Share 2021 VS 2025 VS 2032 Figure 4. Midgut Neuroendocrine Tumor Image Figure 5. Gastroenteropancreatic Neuroendocrine Tumor Image Figure 6. Foregut Neuroendocrine Tumor Image Figure 7. Hindgut Neuroendocrine Tumor Image Figure 8. Global Peptide Receptor Radionuclide Therapy (PRRT) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Peptide Receptor Radionuclide Therapy (PRRT) Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospital Pharmacies Image Figure 11. Online Pharmacies Image Figure 12. Retail Pharmacies Image Figure 13. Global Peptide Receptor Radionuclide Therapy (PRRT) Market Size (US$ Million) & (2021-2032) Figure 14. Global Peptide Receptor Radionuclide Therapy (PRRT) Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Peptide Receptor Radionuclide Therapy (PRRT) Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Peptide Receptor Radionuclide Therapy (PRRT) Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Peptide Receptor Radionuclide Therapy (PRRT) Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Peptide Receptor Radionuclide Therapy (PRRT) Revenue Market Share by Type (2021-2032) Figure 21. Global Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Peptide Receptor Radionuclide Therapy (PRRT) Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Peptide Receptor Radionuclide Therapy (PRRT) Revenue Market Share by Application (2021-2032) Figure 24. North America Peptide Receptor Radionuclide Therapy (PRRT) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Peptide Receptor Radionuclide Therapy (PRRT) Revenue Share by Type (2021-2032) Figure 26. North America Peptide Receptor Radionuclide Therapy (PRRT) Revenue Share by Application (2021-2032) Figure 27. North America Peptide Receptor Radionuclide Therapy (PRRT) Revenue Share by Country (2021-2032) Figure 28. United States Peptide Receptor Radionuclide Therapy (PRRT) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Peptide Receptor Radionuclide Therapy (PRRT) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Peptide Receptor Radionuclide Therapy (PRRT) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Peptide Receptor Radionuclide Therapy (PRRT) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Peptide Receptor Radionuclide Therapy (PRRT) Revenue Share by Type (2021-2032) Figure 33. Europe Peptide Receptor Radionuclide Therapy (PRRT) Revenue Share by Application (2021-2032) Figure 34. Europe Peptide Receptor Radionuclide Therapy (PRRT) Revenue Share by Country (2021-2032) Figure 35. Germany Peptide Receptor Radionuclide Therapy (PRRT) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Peptide Receptor Radionuclide Therapy (PRRT) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Peptide Receptor Radionuclide Therapy (PRRT) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Peptide Receptor Radionuclide Therapy (PRRT) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Peptide Receptor Radionuclide Therapy (PRRT) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Peptide Receptor Radionuclide Therapy (PRRT) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Peptide Receptor Radionuclide Therapy (PRRT) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Peptide Receptor Radionuclide Therapy (PRRT) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Peptide Receptor Radionuclide Therapy (PRRT) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Peptide Receptor Radionuclide Therapy (PRRT) Revenue Share by Type (2021-2032) Figure 45. China Peptide Receptor Radionuclide Therapy (PRRT) Revenue Share by Application (2021-2032) Figure 46. Asia Peptide Receptor Radionuclide Therapy (PRRT) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Peptide Receptor Radionuclide Therapy (PRRT) Revenue Share by Type (2021-2032) Figure 48. Asia Peptide Receptor Radionuclide Therapy (PRRT) Revenue Share by Application (2021-2032) Figure 49. Asia Peptide Receptor Radionuclide Therapy (PRRT) Revenue Share by Region (2021-2032) Figure 50. Japan Peptide Receptor Radionuclide Therapy (PRRT) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Peptide Receptor Radionuclide Therapy (PRRT) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Peptide Receptor Radionuclide Therapy (PRRT) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Peptide Receptor Radionuclide Therapy (PRRT) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Peptide Receptor Radionuclide Therapy (PRRT) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Peptide Receptor Radionuclide Therapy (PRRT) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Peptide Receptor Radionuclide Therapy (PRRT) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Peptide Receptor Radionuclide Therapy (PRRT) Revenue Share by Type (2021-2032) Figure 58. SAMEA Peptide Receptor Radionuclide Therapy (PRRT) Revenue Share by Application (2021-2032) Figure 59. SAMEA Peptide Receptor Radionuclide Therapy (PRRT) Revenue Share by Country (2021-2032) Figure 60. Brazil Peptide Receptor Radionuclide Therapy (PRRT) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Peptide Receptor Radionuclide Therapy (PRRT) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Peptide Receptor Radionuclide Therapy (PRRT) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Peptide Receptor Radionuclide Therapy (PRRT) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Peptide Receptor Radionuclide Therapy (PRRT) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Peptide Receptor Radionuclide Therapy (PRRT) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Peptide Receptor Radionuclide Therapy (PRRT) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Peptide Receptor Radionuclide Therapy (PRRT) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Peptide Receptor Radionuclide Therapy (PRRT) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Peptide Receptor Radionuclide Therapy (PRRT) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Peptide Receptor Radionuclide Therapy (PRRT) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Midgut Neuroendocrine Tumor
  • Gastroenteropancreatic Neuroendocrine Tumor
  • Foregut Neuroendocrine Tumor
  • Hindgut Neuroendocrine Tumor
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • Aurobindo Pharma
  • Curium Pharmaceuticals
  • Lantheus
  • Mundipharma
  • Bayer
  • Novartis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Peptide Receptor Radionuclide Therapy (PRRT) Market by Type
  3. 1.2.1 Global Peptide Receptor Radionuclide Therapy (PRRT) Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Midgut Neuroendocrine Tumor
  5. 1.2.3 Gastroenteropancreatic Neuroendocrine Tumor
  6. 1.2.4 Foregut Neuroendocrine Tumor
  7. 1.2.5 Hindgut Neuroendocrine Tumor
  8. 1.3 Peptide Receptor Radionuclide Therapy (PRRT) Market by Application
  9. 1.3.1 Global Peptide Receptor Radionuclide Therapy (PRRT) Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital Pharmacies
  11. 1.3.3 Online Pharmacies
  12. 1.3.4 Retail Pharmacies
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Peptide Receptor Radionuclide Therapy (PRRT) Market Dynamics
  1. 2.1 Peptide Receptor Radionuclide Therapy (PRRT) Industry Trends
  2. 2.2 Peptide Receptor Radionuclide Therapy (PRRT) Industry Drivers
  3. 2.3 Peptide Receptor Radionuclide Therapy (PRRT) Industry Opportunities and Challenges
  4. 2.4 Peptide Receptor Radionuclide Therapy (PRRT) Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Peptide Receptor Radionuclide Therapy (PRRT) Market Perspective (2021-2032)
  2. 3.2 Global Peptide Receptor Radionuclide Therapy (PRRT) Growth Trends by Region
  3. 3.2.1 Global Peptide Receptor Radionuclide Therapy (PRRT) Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Peptide Receptor Radionuclide Therapy (PRRT) Market Size by Region (2021-2026)
  5. 3.2.3 Global Peptide Receptor Radionuclide Therapy (PRRT) Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Players
  2. 4.1.1 Global Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Players (2021-2026)
  3. 4.1.2 Global Peptide Receptor Radionuclide Therapy (PRRT) Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Peptide Receptor Radionuclide Therapy (PRRT) Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Peptide Receptor Radionuclide Therapy (PRRT) Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Peptide Receptor Radionuclide Therapy (PRRT) Key Players Headquarters & Area Served
  7. 4.4 Global Peptide Receptor Radionuclide Therapy (PRRT) Players, Product Type & Application
  8. 4.5 Global Peptide Receptor Radionuclide Therapy (PRRT) Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Peptide Receptor Radionuclide Therapy (PRRT) Market CR5 and HHI
  11. 4.6.3 2025 Peptide Receptor Radionuclide Therapy (PRRT) Tier 1, Tier 2, and Tier 3
5 Peptide Receptor Radionuclide Therapy (PRRT) Market Size by Type
  1. 5.1 Global Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2021-2032)
  3. 5.3 Global Peptide Receptor Radionuclide Therapy (PRRT) Revenue Market Share by Type (2021-2032)
6 Peptide Receptor Radionuclide Therapy (PRRT) Market Size by Application
  1. 6.1 Global Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2021-2032)
  3. 6.3 Global Peptide Receptor Radionuclide Therapy (PRRT) Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Aurobindo Pharma
  2. 7.1.1 Aurobindo Pharma Company Information
  3. 7.1.2 Aurobindo Pharma Business Overview
  4. 7.1.3 Aurobindo Pharma Peptide Receptor Radionuclide Therapy (PRRT) Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Aurobindo Pharma Peptide Receptor Radionuclide Therapy (PRRT) Product Portfolio
  6. 7.1.5 Aurobindo Pharma Recent Developments
  7. 7.2 Curium Pharmaceuticals
  8. 7.2.1 Curium Pharmaceuticals Company Information
  9. 7.2.2 Curium Pharmaceuticals Business Overview
  10. 7.2.3 Curium Pharmaceuticals Peptide Receptor Radionuclide Therapy (PRRT) Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Curium Pharmaceuticals Peptide Receptor Radionuclide Therapy (PRRT) Product Portfolio
  12. 7.2.5 Curium Pharmaceuticals Recent Developments
  13. 7.3 Lantheus
  14. 7.3.1 Lantheus Company Information
  15. 7.3.2 Lantheus Business Overview
  16. 7.3.3 Lantheus Peptide Receptor Radionuclide Therapy (PRRT) Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Lantheus Peptide Receptor Radionuclide Therapy (PRRT) Product Portfolio
  18. 7.3.5 Lantheus Recent Developments
  19. 7.4 Mundipharma
  20. 7.4.1 Mundipharma Company Information
  21. 7.4.2 Mundipharma Business Overview
  22. 7.4.3 Mundipharma Peptide Receptor Radionuclide Therapy (PRRT) Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Mundipharma Peptide Receptor Radionuclide Therapy (PRRT) Product Portfolio
  24. 7.4.5 Mundipharma Recent Developments
  25. 7.5 Bayer
  26. 7.5.1 Bayer Company Information
  27. 7.5.2 Bayer Business Overview
  28. 7.5.3 Bayer Peptide Receptor Radionuclide Therapy (PRRT) Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Bayer Peptide Receptor Radionuclide Therapy (PRRT) Product Portfolio
  30. 7.5.5 Bayer Recent Developments
  31. 7.6 Novartis
  32. 7.6.1 Novartis Company Information
  33. 7.6.2 Novartis Business Overview
  34. 7.6.3 Novartis Peptide Receptor Radionuclide Therapy (PRRT) Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Novartis Peptide Receptor Radionuclide Therapy (PRRT) Product Portfolio
  36. 7.6.5 Novartis Recent Developments
8 North America
  1. 8.1 North America Peptide Receptor Radionuclide Therapy (PRRT) Revenue (2021-2032)
  2. 8.2 North America Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2021-2032)
  3. 8.2.1 North America Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2021-2026)
  4. 8.2.2 North America Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2027-2032)
  5. 8.3 North America Peptide Receptor Radionuclide Therapy (PRRT) Revenue Share by Type (2021-2032)
  6. 8.4 North America Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2021-2032)
  7. 8.4.1 North America Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2021-2026)
  8. 8.4.2 North America Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2027-2032)
  9. 8.5 North America Peptide Receptor Radionuclide Therapy (PRRT) Revenue Share by Application (2021-2032)
  10. 8.6 North America Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Country
  11. 8.6.1 North America Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Country (2021-2026)
  13. 8.6.3 North America Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Peptide Receptor Radionuclide Therapy (PRRT) Revenue (2021-2032)
  2. 9.2 Europe Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2021-2032)
  3. 9.2.1 Europe Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2021-2026)
  4. 9.2.2 Europe Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2027-2032)
  5. 9.3 Europe Peptide Receptor Radionuclide Therapy (PRRT) Revenue Share by Type (2021-2032)
  6. 9.4 Europe Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2021-2032)
  7. 9.4.1 Europe Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2021-2026)
  8. 9.4.2 Europe Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2027-2032)
  9. 9.5 Europe Peptide Receptor Radionuclide Therapy (PRRT) Revenue Share by Application (2021-2032)
  10. 9.6 Europe Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Country
  11. 9.6.1 Europe Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Country (2021-2026)
  13. 9.6.3 Europe Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Peptide Receptor Radionuclide Therapy (PRRT) Revenue (2021-2032)
  2. 10.2 China Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2021-2032)
  3. 10.2.1 China Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2021-2026)
  4. 10.2.2 China Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2027-2032)
  5. 10.3 China Peptide Receptor Radionuclide Therapy (PRRT) Revenue Share by Type (2021-2032)
  6. 10.4 China Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2021-2032)
  7. 10.4.1 China Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2021-2026)
  8. 10.4.2 China Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2027-2032)
  9. 10.5 China Peptide Receptor Radionuclide Therapy (PRRT) Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Peptide Receptor Radionuclide Therapy (PRRT) Revenue (2021-2032)
  2. 11.2 Asia Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2021-2032)
  3. 11.2.1 Asia Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2021-2026)
  4. 11.2.2 Asia Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2027-2032)
  5. 11.3 Asia Peptide Receptor Radionuclide Therapy (PRRT) Revenue Share by Type (2021-2032)
  6. 11.4 Asia Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2021-2032)
  7. 11.4.1 Asia Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2021-2026)
  8. 11.4.2 Asia Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2027-2032)
  9. 11.5 Asia Peptide Receptor Radionuclide Therapy (PRRT) Revenue Share by Application (2021-2032)
  10. 11.6 Asia Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Country
  11. 11.6.1 Asia Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Country (2021-2026)
  13. 11.6.3 Asia Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Peptide Receptor Radionuclide Therapy (PRRT) Revenue (2021-2032)
  2. 12.2 SAMEA Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Type (2027-2032)
  5. 12.3 SAMEA Peptide Receptor Radionuclide Therapy (PRRT) Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Application (2027-2032)
  9. 12.5 SAMEA Peptide Receptor Radionuclide Therapy (PRRT) Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Country
  11. 12.6.1 SAMEA Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst